A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations

Clinical trial NCT04639219 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04639219
Sponsor: AstraZeneca
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast

Start date: 2020-12-30
Primary completion: 2023-01-25
Enrollment: 102

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.